Literature DB >> 22836588

Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population.

Yuki Suzaki, Naoto Uemura, Masakiyo Hosokawa, Kyoichi Ohashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22836588     DOI： 10.1007/s00228-012-1352-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants.

Authors:  Hao-Jie Zhu; Bryan Brinda; Tanya E Froehlich; John S Markowitz
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

2.  The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.

Authors:  Yuki Suzaki; Naoto Uemura; Makoto Takada; Tetsuji Ohyama; Akiko Itohda; Takuya Morimoto; Hiromitsu Imai; Hajime Hamasaki; Akihiro Inano; Masakiyo Hosokawa; Masato Tateishi; Kyoichi Ohashi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-07       Impact factor: 2.953

3.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Hong-Jie Yuan; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Robert Malcolm; Julie A Johnson; Geri L Youngblood; Douglas H Sweet; Taimour Y Langaee; John S Markowitz
Journal:  Am J Hum Genet       Date:  2008-05-15       Impact factor: 11.025

4.  Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.

Authors:  E K Tarkiainen; J T Backman; M Neuvonen; P J Neuvonen; M Schwab; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

5.  Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.

Authors:  Hao-Jie Zhu; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922
  5 in total
  2 in total

Review 1.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.

Authors:  Lucy Her; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-12-23       Impact factor: 3.922

2.  Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.

Authors:  Jiapeng Li; Jian Shi; Jingcheng Xiao; Lana Tran; Xinwen Wang; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2021-12-21       Impact factor: 3.922
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.